Encouraging news 🙂
The pharmaceutical company, Gilead, has announced results from their Phase 2 trial of their drug for PSC, GS-9674. They report GS-9674 led to significant improvements in liver biochemistry and markers of cholestasis in PSC patients.
“Patients living with PSC urgently need effective and tolerable treatment options,” said Michael Trauner, MD, presenting author and Head of the Division of Gastroenterology and Hepatology at the Medical University of Vienna, Austria. “These Phase 2 results are encouraging in terms of beneficial changes in liver biochemistry, markers of bile acid homeostasis, and patient-reported outcome measures. We look forward to further determining the safety and efficacy of this investigational agent.”